lorcaserin   Click here for help

GtoPdb Ligand ID: 2941

Synonyms: APD-356 | Belviq®
Approved drug
lorcaserin is an approved drug (FDA (2012))
Compound class: Synthetic organic
Comment: Lorcaserin is a selective, orally available and CNS active serotonin 2C receptor agonist that modulates appetite [2-3,5-6]. Cardiovascular safety in obese/overweight patients was reported by Bohula et al. (2018) [1].
Clinical formulations contain lorcaserin hydrochloride (PubChem CID 11673085).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 0
Topological polar surface area 12.03
Molecular weight 195.08
XLogP 2.45
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Clc1ccc2c(c1)C(C)CNCC2
Isomeric SMILES Clc1ccc2c(c1)[C@@H](C)CNCC2
InChI InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1
InChI Key XTTZERNUQAFMOF-QMMMGPOBSA-N
No information available.
Summary of Clinical Use Click here for help
Lorcaserin was approved by the FDA in 2012 as an adjuncttive weight-loss therapy that could be used with caloric restriction and increased physical activity in the management of chronic obesity, in patients with BMI ≥27kg/m2. In February 2019 this approval was terminated and the drug was withdrawn from the US market, because a 5 year safety trial revealed increased cancer occurrence associated with lorcaserin therapy. The increased cancer risk was considered by the FDA to outweigh the drug's clinical benefit.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Lorcaserin is a selective 5-HT2C receptor agonist and acts as an anorectic, achieving weight-loss.
External links Click here for help